These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33068236)

  • 1. Obtaining EQ-5D-5L utilities from the disease specific quality of life Alzheimer's disease scale: development and results from a mapping study.
    Rombach I; Iftikhar M; Jhuti GS; Gustavsson A; Lecomte P; Belger M; Handels R; Castro Sanchez AY; Kors J; Hopper L; Olde Rikkert M; Selbæk G; Stephan A; Sikkes SAM; Woods B; Gonçalves-Pereira M; Zanetti O; Ramakers IHGB; Verhey FRJ; Gallacher J; Actifcare Consortium ; LeARN Consortium ; Landeiro F; Gray AM;
    Qual Life Res; 2021 Mar; 30(3):867-879. PubMed ID: 33068236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Should We Capture Health State Utility in Dementia? Comparisons of DEMQOL-Proxy-U and of Self- and Proxy-Completed EQ-5D-5L.
    Martin A; Meads D; Griffiths AW; Surr CA
    Value Health; 2019 Dec; 22(12):1417-1426. PubMed ID: 31806199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mapping ALSFRS-R and ALSUI to EQ-5D in Patients with Motor Neuron Disease.
    Moore A; Young CA; Hughes DA
    Value Health; 2018 Nov; 21(11):1322-1329. PubMed ID: 30442280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.
    Meregaglia M; Borsoi L; Cairns J; Tarricone R
    Eur J Health Econ; 2019 Mar; 20(2):181-193. PubMed ID: 28948436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D.
    Lamu AN; Olsen JA
    Qual Life Res; 2018 Nov; 27(11):2823-2839. PubMed ID: 30173314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The estimation of a preference-based single index for the IBS-QoL by mapping to the EQ-5D-5L in patients with irritable bowel syndrome.
    Sturkenboom R; Keszthelyi D; Brandts L; Weerts ZZRM; Snijkers JTW; Masclee AAM; Essers BAB
    Qual Life Res; 2022 Apr; 31(4):1209-1221. PubMed ID: 34546554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mapping analyses to estimate EQ-5D utilities and responses based on Oxford Knee Score.
    Dakin H; Gray A; Murray D
    Qual Life Res; 2013 Apr; 22(3):683-94. PubMed ID: 22555470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Converting Parkinson-Specific Scores into Health State Utilities to Assess Cost-Utility Analysis.
    Chen G; Garcia-Gordillo MA; Collado-Mateo D; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellán-Perpiñán JM; Sánchez-Martínez FI
    Patient; 2018 Dec; 11(6):665-675. PubMed ID: 29876865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating EQ-5D utilities based on the Short-Form Long Term Conditions Questionnaire (LTCQ-8).
    Tsiachristas A; Potter CM; Rocks S; Peters M; Cundell M; McShane R; Batchelder L; Fox D; Forder JE; Jones K; Waite F; Freeman D; Fitzpatrick R
    Health Qual Life Outcomes; 2020 Aug; 18(1):279. PubMed ID: 32795317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acceptability and Validity of the EQ-5D in Patients Living With Dementia.
    Michalowsky B; Xie F; Kohlmann T; Gräske J; Wübbeler M; Thyrian JR; Hoffmann W
    Value Health; 2020 Jun; 23(6):760-767. PubMed ID: 32540234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indirect and Direct Mapping of the Cancer-Specific EORTC QLQ-C30 onto EQ-5D-5L Utility Scores.
    Meunier A; Soare A; Chevrou-Severac H; Myren KJ; Murata T; Longworth L
    Appl Health Econ Health Policy; 2022 Jan; 20(1):119-131. PubMed ID: 34554442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of algorithms to estimate the EQ-5D-5L from the FACT-L in patients with lung cancer: a mapping study.
    Jiang L; Zhou H; Yang Q; Luo X; Huang D
    Qual Life Res; 2024 Mar; 33(3):805-816. PubMed ID: 38148367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generating EQ-5D-5L health utility scores from BASDAI and BASFI: a mapping study in patients with axial spondyloarthritis using longitudinal UK registry data.
    Neilson AR; Jones GT; Macfarlane GJ; Pathan EM; McNamee P
    Eur J Health Econ; 2022 Nov; 23(8):1357-1369. PubMed ID: 35113270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obtaining EQ-5D-3L utility index from the health status scale of traditional Chinese medicine (TCM-HSS) based on a mapping study.
    Wang L; Lu Y; Dai Z; Shi P; Xu J; Chang F; Lu Y
    Health Qual Life Outcomes; 2022 Dec; 20(1):164. PubMed ID: 36522665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study.
    Vilsbøll AW; Kragh N; Hahn-Pedersen J; Jensen CE
    Qual Life Res; 2020 Sep; 29(9):2529-2539. PubMed ID: 32297132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do country-specific preference weights matter in the choice of mapping algorithms? The case of mapping the Diabetes-39 onto eight country-specific EQ-5D-5L value sets.
    Lamu AN; Chen G; Gamst-Klaussen T; Olsen JA
    Qual Life Res; 2018 Jul; 27(7):1801-1814. PubMed ID: 29569014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of algorithms to estimate EQ-5D and derive health utilities from WHOQOL-HIV Bref: a mapping study.
    Castro R; De Boni RB; Perazzo H; Grinsztejn B; Veloso VG; Ribeiro-Alves M
    Qual Life Res; 2020 Sep; 29(9):2497-2508. PubMed ID: 32451983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma.
    Arnold DT; Rowen D; Versteegh MM; Morley A; Hooper CE; Maskell NA
    Health Qual Life Outcomes; 2015 Jan; 13():6. PubMed ID: 25613110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mapping study in mainland China: predicting EQ-5D-5L utility scores from the psoriasis disability index.
    Su J; Liu T; Li S; Zhao Y; Kuang Y
    J Med Econ; 2020 Jul; 23(7):737-743. PubMed ID: 32223358
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.